EUVIMEDEUVIMED entdecken
Crossref

Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer

Xiaohui Qian, Huang Yang, Ziqiang Ye, Bingqiang Gao, Zhefeng Qian, Yuan Ding, Zhengwei Mao iD, Yang Du iD, Weilin Wang

ACS Nano · 18.06.2024 · 18 (24) · 15864-15877

DOI: 10.1021/acsnano.4c02947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, online erschienen am 03.06.2024. Verfasst von Xiaohui Qian und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Celecoxib, Paclitaxel, Immunogenic Cell Death. Die Arbeit wurde bisher 80-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: Zhejiang University, Science and Technology Department of Zhejiang Province, Fundamental Research Funds for the Central Universities.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCelecoxibPaclitaxelImmunogenic Cell DeathAnimalsMiceHumansFemaleCell Line, TumorMice, Inbred BALB CLiposomes

Stichwörter der Autor:innen

celecoxibdrug combinationimmunogenic cell deathnanomedicinetriple-negative breast cancer

Substanzen

CelecoxibPaclitaxelLiposomes

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, Zhejiang, China.
  • Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou 310009, Zhejiang, China.
  • Research Center of Diagnosis and Treatment Technology for Hepatocellular Carcinoma of Zhejiang Province, Hangzhou 310009, Zhejiang, China.
  • National Innovation Center for Fundamental Research on Cancer Medicine, Hangzhou 310009, Zhejiang, China.
  • Cancer Center, Zhejiang University, Hangzhou 310058, Zhejiang, China.
  • ZJU-Pujian Research & Development Center of Medical Artificial Intelligence for Hepatobiliary and Pancreatic Disease, Hangzhou 310058, Zhejiang, China.

ORCID-Profile: Zhengwei Mao, Yang Du

Förderung

  • Zhejiang University
  • Science and Technology Department of Zhejiang Province
  • Fundamental Research Funds for the Central Universities
  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province
  • Key Laboratory of Intelligent Preventive Medicine of Zhejiang Province

Zitieren

APA

Qian, X., Yang, H., Ye, Z., Gao, B., Qian, Z., Ding, Y., Mao, Z., Du, Y., & Wang, W. (2024). Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer. ACS Nano, 18(24), 15864-15877. https://doi.org/10.1021/acsnano.4c02947

Vancouver

Qian X, Yang H, Ye Z, Gao B, Qian Z, Ding Y, et al. Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer. ACS Nano. 2024;18(24):15864-15877. doi:10.1021/acsnano.4c02947

BibTeX
@article{Qian2024,
  author = {Qian, Xiaohui and Yang, Huang and Ye, Ziqiang and Gao, Bingqiang and Qian, Zhefeng and Ding, Yuan and Mao, Zhengwei and Du, Yang and Wang, Weilin},
  title = {Celecoxib Augments Paclitaxel-Induced Immunogenic Cell Death in Triple-Negative Breast Cancer},
  journal = {ACS Nano},
  year = {2024},
  volume = {18},
  number = {24},
  pages = {15864--15877},
  doi = {10.1021/acsnano.4c02947}
}
Kostenlos starten →